article thumbnail

JPM24: Riding label expansions and launches, AZ plots course toward 'industry-leading growth' by 2030

Fierce Pharma

In AZ's push to reach industry-leading growth by 2030, confidence is key, chief financial officer Aradhana Sarin said at the J.P. With a late-stage pipeline spanning more than 120 clinical trials and a firm grasp of five major disease areas, AstraZeneca appears confident heading into 2024. | Morgan Healthcare Conference.

Labelling 116
article thumbnail

Endometriosis market projected to grow at a CAGR of 10% between 2020 and 2030

Pharmaceutical Technology

The endometriosis market is expected to grow from $1.05bn in 2020 to $2.72bn in 2030 at a compound annual growth rate (CAGR) of 10.0% The figure below summarises the endometriosis market growth across the 7MM from 2020 to 2030. At the end of 2030, the US will contribute approximately 81.3% of 7MM sales.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

CD19 CAR-T agents to boost blood cancer market

European Pharmaceutical Review

Yescarta for blood cancer Yescarta is targeting expansions into the first line for diffuse large B-cell lymphoma (DLBCL) and second line for follicular lymphoma in 2030. It is set to retain its market-leading position as the most lucrative CD19 CAR-T agent in NHL, with annual sales reaching $1.7

article thumbnail

Eli Lilly achieving significant gains in obesity results

Pharmaceutical Technology

In addition, Mounjaro is estimated to gain sales of around $20bn by 2030 and become the leading GLP-1 in the obesity market, as well as in T2D. Mounjaro’s approval in 2022 for T2D has already led to many prescribers providing the therapy off-label to their patients to help them lose weight.

article thumbnail

Sun Pharma agrees deal to buy alopecia player Concert

pharmaphorum

.” A recent report from Clarivate highlighted ritlecitinib as one of 14 potential blockbusters to watch this year, pointing to its rapid onset of action and expected label for both adults and adolescents – Olumiant is so far only approved for use in adults. The report predicts that the alopecia areata market will grow to as much as $2.5

article thumbnail

FDA expands use of Abbott’s heart sensor with new approval

pharmaphorum

The FDA has approved expanded labelling for Abbott’s CardioMEMS HF System, an implantable sensor that provides an early warning of worsening heart failure, that could make it an option for more than a million more patients. More than 6.2

FDA 64
article thumbnail

The data are in – so will Gilead’s Trodelvy achieve its potential?

pharmaphorum

He is giving Trodelvy a 40% chance of approval and launch with a third-line label in HR+/HER2- breast cancer in 2024, with $900 million in potential sales from the indication, if TROPiCS-02 is positive at the final readout. The company said it “remains confident in that goal.” appeared first on.